US EditionPrices for new US drugs doubled in 4 years as focus on rare disease grows
- U.S. Prices for newly launched drugs more than doubled between 2021 and 2024, reaching a median of over $370,000 last year.
- This rise reflects increased development of therapies for rare diseases, which are often priced high due to small patient populations.
- In 2024, 72% of new drugs targeted orphan diseases affecting fewer than 200,000 Americans, with over 40% addressing oncology conditions.
- Record prices include Lenmeldy at $4.25 million for a one-time gene therapy launched in 2023, while Pfizer's $3.5 million Beqvez therapy was withdrawn due to low demand.
- The trend suggests sustained high prices until reducing development costs, as stakeholders emphasize these drugs’ value despite concerns about overall affordability.
7 Articles
7 Articles
Pharmalittle: We're reading about rising drug prices, Cigna's plan for weight loss drugs, and more
Top of the morning to you. Gray skies are once again hovering over the soggy Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Remember, a prescription is not required, so rebates do not have to …
Prices for new US drugs doubled in 4 years as focus on rare disease grows
U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged scientific advances to develop more therapies for rare diseases, which typically command high prices, a Reuters analysis found.
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
